BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25426669)

  • 1. Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia.
    Prijić S; Ugrina I; Labar B; Nemet D; Batinić J; Zadro R; Ries S; Gjadrov-Kuvedžić K; Davidović S; Batinić D
    Leuk Lymphoma; 2015; 56(8):2281-8. PubMed ID: 25426669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway.
    Ma L; Kuai WX; Sun XZ; Lu XC; Yuan YF
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7867-7876. PubMed ID: 30536332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia.
    Serrano-López J; Serrano J; Figueroa V; Torres-Gomez A; Tabares S; Casaño J; Fernandez-Escalada N; Sánchez-Garcia J
    Haematologica; 2013 Dec; 98(12):1877-85. PubMed ID: 23812937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia.
    Ma H; Zhou H; Li P; Song X; Miao X; Li Y; Jia L
    Biochim Biophys Acta; 2014 Sep; 1842(9):1681-92. PubMed ID: 24953795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
    Tamburini J; Elie C; Bardet V; Chapuis N; Park S; Broët P; Cornillet-Lefebvre P; Lioure B; Ugo V; Blanchet O; Ifrah N; Witz F; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2007 Aug; 110(3):1025-8. PubMed ID: 17426258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
    Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia.
    Ricciardi MR; Mirabilii S; Licchetta R; Piedimonte M; Tafuri A
    Adv Biol Regul; 2017 Aug; 65():36-58. PubMed ID: 28549531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.
    Liu Y; Chen Y; Liu Y; Li M; Zhang Y; Shi L; Yang L; Li T; Li Y; Jiang Z; Liu Y; Wang C; Wang S
    J Transl Med; 2022 Dec; 20(1):612. PubMed ID: 36550462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.
    Machaczka M; Wahlin BE; Piatkowska-Jakubas B; Rucinska M; Jurczak W; Balana-Nowak A; Klimkowska M; Hägglund H; Skotnicki AB
    Med Oncol; 2012 Sep; 29(3):2070-6. PubMed ID: 21861206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.
    Liang H; Zheng QL; Fang P; Zhang J; Zhang T; Liu W; Guo M; Robinson CL; Chen SB; Chen XP; Chen FP; Zeng H
    Sci Rep; 2017 Jan; 7():40361. PubMed ID: 28098170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
    Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
    Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
    Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H
    Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
    Pelloski CE; Lin E; Zhang L; Yung WK; Colman H; Liu JL; Woo SY; Heimberger AB; Suki D; Prados M; Chang S; Barker FG; Fuller GN; Aldape KD
    Clin Cancer Res; 2006 Jul; 12(13):3935-41. PubMed ID: 16818690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ankyrin repeat and suppressor of cytokine signaling (SOCS) box-containing protein (ASB) 15 alters differentiation of mouse C2C12 myoblasts and phosphorylation of mitogen-activated protein kinase and Akt.
    McDaneld TG; Spurlock DM
    J Anim Sci; 2008 Nov; 86(11):2897-902. PubMed ID: 18641171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of Multidrug Resistance of Acute Myeloid Leukemia Cells by Cocultured Stromal Cells via Upregulation of the PI3K/Akt Signaling Pathway.
    Chen P; Jin Q; Fu Q; You P; Jiang X; Yuan Q; Huang H
    Oncol Res; 2016; 24(4):215-23. PubMed ID: 27656831
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
    Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
    [No Abstract]   [Full Text] [Related]  

  • 19. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
    Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
    Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
    Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.